An ex vivo photochemical treatment (PCT) process was developed to inactivate pathogens in fresh frozen plasma (PCT-FFP). A prospective, controlled, double-blinded, randomized study was conducted to evaluate the efficacy and safety of PCT-FFP 
INTRODUCTION
Although improvements in donor testing have increased the safety of blood components prepared for transfusions, risk from transfusion-transmitted pathogens persists 1 . Transfusion of blood components has been implicated in the transmission of viral, bacterial, and protozoan diseases 2 . Pathogens such as West Nile virus have recently emerged as transfusion-transmitted infectious agents, demonstrating that that new infectious agents continue to enter the donor population, and may pose significant risks to recipients before they can be definitively identified and avoided by sensitive tests 3 .
Development of inactivation processes effective against a broad array of infectious pathogens could provide a measure of safety against transfusion-transmitted infectious agents not routinely screened for or detected by current assays. An ex vivo photochemical treatment (PCT) process utilizing a synthetic psoralen, amotosalen hydrochloride (S-59), has been developed to inactivate pathogens and residual leukocytes in fresh frozen plasma (PCT-FFP) 4 . Preclinical testing indicates that the system is effective in the reduction of a broad range of pathogens in plasma. The pharmacokinetics of select coagulation factors in PCT-FFP have been shown to be comparable to conventional FFP 5, 6 .
Patients with acquired coagulopathy (most frequently due to end-stage liver disease) constitute a significant population requiring treatment with FFP. Patients with these disorders may require large volumes of FFP during a single treatment episode, and many of these patients will require repeated FFP transfusions resulting in exposures to FFP from many different blood donors 7, 8 . This study describes a prospective,
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METHODS

Study Design
This study was a two-arm, randomized, controlled, double-blinded study conducted at five sites in the United States. Eligible patients included those of either gender, age 2 years or older, with an acquired coagulopathy requiring therapeutic or prophylactic FFP transfusion indicated for an invasive procedure or reversal of warfarin therapy. Patients with coagulopathy due to trauma were excluded. No concomitant therapies were specifically excluded with the exception of other investigational therapies within 30 days prior to randomization. After screening and giving informed consent, patients were randomized to receive either PCT-FFP or C-FFP during a 7-day treatment
period. An FFP dose of 15-20 mL/kg was recommended, although the treating physician determined the final dose and rate of administration of study FFP. In some instances, liver transplant patients received a continuous transfusion of FFP for the duration of surgery (typically 5-10 mL/kg/hr).
All patients who received at least one 2-unit plasma transfusion (~400 mL) of C-FFP or PCT-FFP were included in the intent-to-treat (ITT) population. The primary endpoint was the response of the PT and PTT to the first study FFP transfusion.
Secondary efficacy analyses included the recovery of Factor VII one hour after the first transfusion, the correlation of the PT response to the Factor VII level following the initial transfusion, an analysis of covariance to the response in PT and PTT, assessment of clinical hemostasis, the PT and PTT responses to all subsequent transfusions, use of blood components, and safety. Clinical hemostasis was assessed during the 8 hours prior to the first study FFP transfusion and then for 8 hours following the first study FFP transfusion. Study personnel, blinded to treatment assignment, conducted hemostatic assessments using an established bleeding assessment scale, the WHO bleeding criteria, as described for a prior study of platelet transfusion efficacy 9 .
Blood samples were obtained for each patient within 8 hours before and 1 hour after the first FFP transfusion to assess the PT, PTT, S-59 concentration, serum chemistry, hematology, and Factor VII activity. For patients treated with continuous rather than bolus FFP infusions, the end of the transfusion period was defined as an interval of 8 hours without FFP infusion. In these cases, samples for laboratory analyses were obtained within the first hour after cessation of the FFP infusion. PT and PTT values and S-59 samples were drawn before and after each subsequent study FFP transfusion. PT and PTT assays were performed using the methods in use at each study site clinical laboratory.
In addition, blood samples were obtained within 8 hours prior to the first transfusion and at the 6-week follow-up visit for assessment of antibody formation to potential S-59 associated plasma neoantigens. Sera for detection of potential antibodies to S-59 related neoantigens were tested using a previously described solid phase immunoassay 10,11 . All adverse events were recorded according to the NCI-CTC criteria.
Adverse events, including hemorrhagic events, were recorded for 2 weeks after the first transfusion, and major medical adverse events were recorded through 6 weeks post-firsttransfusion. Adverse events were reported by study personnel and reviewed by the principal investigator at each study site.
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Investigational Product
The investigational product, PCT-FFP (Cerus Corporation, Concord, CA), consisted of plasma photochemically treated using the synthetic psoralen, (amotosalen 
Statistical Methods
The primary efficacy endpoints in this study were change in prothrombin time (∆PT) and change in partial thromboplastin time (∆PTT), adjusted for FFP dose and patient body weight, in response to the first study FFP transfusion. Changes in PT and PTT were adjusted for FFP dose (mL/kg) and patient weight using the formulae 13 :
∆ PT N (sec· kg· mL PTT responses not adjusted for FFP dose and patient weight; and to determine the appropriate sample size and power for the an equivalence analysis of the PT and PTT response in this trial. The non-inferiority margins for the change in PT and PTT were prespecified as a difference in reduction of -4.6 seconds for the PT and -4.8 seconds for the PTT. Based on these inferiority margins, a sample size of 120 patients, randomized in a 1:1 ratio, was estimated to provide greater than 80% power to reject the null hypotheses of non-equivalence for the two primary endpoints (PT and PTT) at a 2-sided alpha level of 0.05. The hypotheses to be tested were :
a) The absolute difference in mean PT reduction (PT post -PT pre ), (PT N ), between Test and Control is greater than or equal to 4.6 seconds.
b) The absolute difference in mean PTT reduction, (PTT post -PTT pre ), (PTT N ) between Test and Control, is greater than or equal to 4.8 seconds.
For the co-primary endpoints, observation of a small p-value (e.g., p≤ 0.025 for a 0.025 level of significance) would indicate rejection of the null hypotheses of nonequivalence, and, therefore, confirm equivalence between PCT FFP and C-FFP for the specified margins.
Factor VII increments (IU/dL) and incremental Factor VII recovery (IU/dL/IU/Kg) were determined and mean difference compared by t test. In addition, dose-adjusted PT and PTT responses for all FFP transfusions administered during the 7-day transfusion support period were compared using repeated measures of analysis of variance (ANOVA).
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Fisher's exact test was used for comparison of adverse events.
Collection of intra-operative surgical hemostatic observations and post-operative hemostasis, as measured by hemostatic scoring using a modified version of the WHO bleeding criteria as previously described 9 ; and by review of the medical record of surgical procedures for estimated blood loss, were used to assess clinical hemostasis. The median post-transfusion bleeding grade following FFP transfusion was compared between treatment groups. The Wilcoxon rank sum test was used for comparison of hematology and serum chemistry parameters as well as Grade 2 bleeding. All secondary endpoints were analyzed for differences between treatment groups at the p = 0.05 significance level.
RESULTS
Demographics and Baseline Characteristics
Approximately 250 patients with acquired coagulopathy were screened for enrollment, 132 gave informed consent and were randomized; and 121 patients received at least one FFP transfusion of the assigned study product. The 121 patients transfused with 2 or more units of FFP (~ 400 mL) constituted the ITT analysis group (60 PCT-FFP, 61 C-FFP). The PCT-FFP and C-FFP groups exhibited similar demographics respectively for male gender (52%, 67%), Caucasian race (70%, 75%), age (60±15, 61±
12), A-B-O blood type (40%, 12%, 48% versus 39%,10%, 51%), and concomitant medications (data not shown).
Primary diagnoses at enrollment were similar between treatment groups (Table   3A ). Of these, 51 patients (42%) were transfused for hemostatic support during (Table 3B) .
Primary Efficacy Endpoint Overall Patient Population
The response of the PT to the first FFP transfusion was assessed in 58 (97%)
PCT-FFP and 58 (95%) C-FFP patients. When changes in PT and PTT were adjusted by FFP dose and patient weight, no statistically significant differences in the correction of the PT and PTT were observed between PCT-FFP and C-FFP groups (Table 4 ).
The unadjusted correction of the PT was equivalent between the PCT-FFP and C-FFP groups following the first transfusion ( Table 5 ). The mean difference for change of non-inferiority). The 95% CI for the upper and lower limit of the difference in the PTT response was greater than the pre-specified equivalence margin for the PTT (4.8 seconds). This was due to the large variance in the PTT response, and thus, rejection of inferiority or equivalence could not be confirmed. However, the correction of PTT showed a trend slightly favoring the PCT-FFP group (Table 5) .
OLT Patient Population
Because liver transplant patients generally received larger volumes of FFP and had more substantial surgical procedures than non-transplant patients, the OLT and non-OLT populations were analyzed separately. OLT patients (n = 51) had a mean difference in the absolute PT response between treatment groups of 1.7 seconds (p = 0.103, by noninferiority). The mean difference in the absolute PTT response between treatment groups was 4.1 seconds (p = 0.890, by non-inferiority).
Non-OLT Patient Population
Non-OLT patients (n=70) demonstrated a mean difference in absolute PT response between the treatment groups of 0.6 seconds (p = 0.042, by non-inferiority).
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The mean difference in the absolute PTT response between treatment groups was 3.1 seconds (p = 0.907, by non-inferiority).
Secondary Efficacy Endpoints
Factor VII Levels. The mean dose of Factor VII (IU) transfused with the first transfusion was lower for the PCT-FFP group (1623 ± 1844 versus 2434 ± 3256, p = 0.100) . The mean increment for Factor VII (IU/dL) after the first study transfusion was 12. (Table 7) .
As expected, OLT patients exhibited greater blood component usage than non-OLT patients, but there was no difference in blood component usage within these subgroups between PCT-FFP and C-FFP treatment groups (Table 7) .
S-59 levels were measured prior to transfusion, 5 to 60 minutes after the first study transfusion, and immediately prior to the final study period transfusion to determine trough levels. For all Test patients, the mean peak level (ng/mL) was 5.4 ± 3.6 compared to OLT patients with mean peak level of 8.3 ± 4.0, and non-OLT patients with mean peak level of 3.8 ± 2.0. For all patients, the mean trough level of S-59 (ng/mL) was 2.0 ± 2.0; and despite larger exposures to FFP, mean trough S-59 levels were lower in OLT patients than non-OLT patients (1.4 ± 1.4 versus 2.1 ± 2.2). For comparison, in a Phase 1 study, healthy non-bleeding subjects transfused with 1000 mL of PCT-FFP exhibited mean peak S-59 levels of 11.5 ± 0.8 14 .
Safety Evaluation
Adverse events, by system organ class and preferred term, were reported with similar frequency between PCT-FFP and conventional FFP patients ( 
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Six cases of hepatic artery thrombosis (HAT) were reported (2 in the PCT-FFP group and 4 in the C-FFP group). The incidence of this complication was within the range reported for liver transplantation 15 . The first four cases of HAT occurred within two weeks of OLT surgery and the last transfusion of study FFP, while the remaining two cases of HAT occurred more than four weeks after the last administration of study FFP.
Plasma samples collected pre-and post-transfusion from these patients, as well as samples from PCT-FFP units, indicated that the anti-thrombotic proteins, antithrombin III and Proteins C and S, were conserved comparably between Test and Control patients (Table 9 ). Anticardiolipin antibodies were not present in any of the six patients with HAT ( Table 9 ). The clinical course for each patient with HAT was reviewed by the study Data and Safety Monitoring Board; and none of the cases was attributed to use of study FFP.
There were 21 deaths in the overall study population (12 PCT-FFP, 9 C-FFP). All deaths were consistent with the typical course of hepatic failure, and none were assessed as related to the transfusion of study FFP. Evaluation of changes in coagulation assays is difficult in the setting of liver transplantation due to the non-steady state induced by large volume blood loss. For non-OLT patients with less active bleeding, the performance of PCT-FFP for the PT response was statistically better when compared to transfusion with conventional FFP.
Comparable increases in Factor VII levels and in Factor VII incremental recovery were observed between the PCT-FFP and conventional FFP treatment groups. These findings are consistent with the pharmacokinetic study of Factor VII in non-bleeding subjects 6 ;
and indicate that PCT-FFP can be dosed similarly to conventional FFP. In this study
Factor VII dose, the PT response, and the change in Factor VII levels were significantly correlated. This is relevant information given the complex coagulopathy of patients with Adverse events reported in this trial were consistent with the spectrum of clinical events described in association with severe underlying liver disease 27, 28 . Hepatic artery thrombosis (HAT) is a recognized post-operative complication associated with OLT surgery 15 . It has been reported that solvent detergent-treated plasma has diminished levels of some anti-thrombotic proteins 29, 30 . Because of concerns regarding this complication, the levels of anti-thrombotic proteins in PCT-FFP and in the plasma of post-operative patients were measured during this study. The incidence of HAT was comparable between treatment groups and the levels of anti-thrombotic proteins in PCT-FFP and C-FFP were similar as were the levels in patient plasma.
Studies of FFP transfusion for patients with coagulopathy of liver disease have been conducted for SD-FFP, but were smaller in scope 12, 24 . Randomized trials of MB-FFP have not been reported for patients with acquired coagulopathy of liver disease 31 .
However, in some countries, experience has been reported to indicate increased usage of Factor XIII 108 ± 11 107 ± 11 65 -165 * Coagulation factor activity was measured using standard coagulation assays for retained samples of C-FFP and PCT-FFP taken from 274 to 277 randomly selected units and stored for variable periods of time during the study. The mean volume of PCT-FFP units was 285 ± 3 mL (range 280 to 289 mL). Samples for coagulation assays were obtained after preparation and prior to freezing. Aliquots were stored at -18 ˚C and assayed during the course of the study at approximately the same time as full units were transfused. Approximately, 9,000 PCT-FFP units were prepared during the study. The functional activites (mean ± SD) for coagulation factors proteins were calculated and compared to a reference range for conventional FFP sampled before freezing and stored for variable periods of time. Activity was expressed as mg/dL for fibrinogen and for all other factors, as IU/dL. Factor XIII activity was based on analysis of 14 C-FFP and PCT-FFP units. † Reference ranges for C-FFP were determined using samples obtained from plasma units (n = 274 -277) obtained after collection and prior to PCT processing and freezing. The reference range was defined at the 95% central interval for coagulation factor activity in plasma derived from CPD-A whole blood using approved collection systems (Transfusion Therapies, Baxter Healthcare Corporation, Deerfield, IL).
For All available reserved plasma samples were assayed after the diagnosis of HAT was reported. Baseline samples were obtained prior to the first study transfusion and after the first transfusion (POST). Additional samples were obtained for two patients and end of study. 
